Alyftrek is approved as a new treatment for cystic fibrosis, while the FDA expanded the label for Trikafta to include additional genetic mutations.
The drug combo is the first dual checkpoint inhibitor therapy approved in Europe for first-line metastatic MSI-H or dMMR colorectal cancer.
NEW YORK – 2024 was a banner year of "firsts" in the gene therapy space, as the US Food and Drug Administration greenlit ...
NEW YORK – AstraZeneca on Monday said the European Commission approved its tyrosine kinase inhibitor Tagrisso (osimertinib) as a treatment for patients with advanced, unresectable non-small cell lung ...
The firms have teamed up on a Phase I trial to evaluate the off-the-shelf cell therapy SN301A in patients with advanced GPC3-expressing liver cancers.
R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.
The company separately said it has started treating patients within a Phase III trial testing an ASO drug for Angelman syndrome.
The drugmaker said that the agents vibostolimab and favezelimab failed to show benefit across numerous trials.
NEW YORK – Ideaya Biosciences said Monday that it plans to develop a KAT6/7 inhibitor, IDE251, as treatment for breast and lung cancer patients whose tumors harbor 8p11 amplifications.
The firms are developing the autologous CAR T-cell therapy IB-T101 as a treatment for clear cell renal cell carcinoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback